Fig. 4From: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degenerationDistribution of patients by absolute final BCVA subgroups (< 50, 50–55, 55–70 and ≥ 70 letters). *n = 125. Per-protocol population. BCVA = best–corrected visual acuityBack to article page